From March 30 to April 2, Washington became the global hub for vaccines hosting the World Vaccine Congress at Walter E. Washington Convention Centre, which brings together leading experts from across the field of vaccines and global health.
Laura Ferrer, R&D Director of the Human Health Division at HIPRA, participated in a session led by HIPRA Biotech Services titled “Annual Adaptation of Recombinant Protein COVID-19 Vaccine: Process, Challenges and Opportunities”, part of the Influenza & Respiratory track.
Ferrer shared insights on adaptable vaccine platforms and the need to accelerate development capabilities in response to emerging health threats, key priorities at the core of the SPEEDCELL project. As she highlighted, “strengthening adaptable vaccine platforms and accelerating development capabilities will be essential to fit the goals of the 100 Days Mission.”
A strong alignment with SPEEDCELL objectives
Her presentation also reflected how platform-based approaches enable continuous adaptation to new variants, supported by robust manufacturing processes and end-to-end control of the value chain, from early development to industrial production.
In this context, initiatives such as SPEEDCELL aim to contribute to faster and more flexible vaccine development strategies, aligned with the European ambition to improve preparedness and response capacity in future health emergencies, and supporting the ambition of the 100 Days Mission.
This edition of the World Vaccine Congress has brought together inspirational conversations from the global vaccine ecosystem, and their discussions reinforce the importance of strengthening manufacturing capabilities and collaborative frameworks to ensure a faster and more effective response to future health crises.
